论文部分内容阅读
丙型肝炎由丙型肝炎病毒(hepatitis C virus,HCV)感染所致,约80%感染者可发展成慢性肝炎,甚至肝硬化和肝癌。目前,临床主要应用干扰素结合利巴韦林联合疗法治疗丙型肝炎,但治疗后病毒有效应答率不高,并伴有明显的副作用产生,迫切需要研发靶向药物。随着HCV体外细胞培养技术获得的突破性进展以及在此基础上各种药物筛选方法的建立,利用现有的筛选模型筛选靶向药物成为抗病毒药物研发的重要途径。近年来,将GFP、hRLuc等报告基因插入HCV基因组中改造成具有明显标记的高通量药物筛选体系,已初步筛选出一些有效的HCV靶向药物,就现有抗丙型肝炎病毒靶向药物及抗病毒药物筛选方法进行综述。
Hepatitis C is caused by hepatitis C virus (HCV) infection, and about 80% of infected people develop chronic hepatitis, even cirrhosis and liver cancer. At present, the clinical application of interferon combined with ribavirin combination therapy in the treatment of hepatitis C, but after treatment, the effective rate of the virus is not high, accompanied by significant side effects, the urgent need to develop targeted drugs. With the breakthrough of HCV in vitro cell culture technology and the establishment of various drug screening methods based on this, it is an important way to screen targeted drugs with the existing screening models for the development of antiviral drugs. In recent years, GFP, hRLuc and other reporter gene inserted into the HCV genome into a marked high-throughput drug screening system has been initially screened some effective HCV targeted drugs, the existing anti-hepatitis C virus targeted drugs And anti-virus drug screening methods are reviewed.